Skip to main content
Top
Published in: Indian Journal of Hematology and Blood Transfusion 2/2020

01-04-2020 | Primary Myelofibrosis | Images

Systemic Mastocytosis with Associated Primary Myelofibrosis

Authors: Marianna Greco, Giovanni Caocci, Roberto Mascia, Sonia Nemolato, Margherita Deidda, Maria Pina Simula, Maria Pina Barca, Sandra Orrù, Giorgio La Nasa

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 2/2020

Login to get access

Excerpt

Systemic mastocytosis (SM) is a chronic myeloproliferative neoplasm characterized by the infiltration of atypical mast cells (MC). The major SM diagnostic criterion is the multifocal clustering of mast cells in the bone marrow. Minor SM criteria include an abnormal MC morphology and expression of CD25/CD2, an activating mutation at codon 816 of KIT, and a persistent serum tryptase concentration of > 20 ng/mL. When the major and at least 1 minor criterion or 3 minor criteria are fulfilled, the SM diagnosis is established. The World Health Organization (WHO) classification has recently recognized a subgroup of SM with an associated hematological neoplasm (SM-AHN), which is characterized by the presence of a concurrent neoplasm [1]. We present the case of a 72-year old woman suffering from SM associated with myelofibrosis (MF) referred to our center due to mild anemia and leukocytosis (Hb, 10.2 g/dL, WBC, 11,900/mm3, PLT, 368,000/mm3). The patient complained of fatigue, pruritus and weight loss. Physical examination revealed splenomegaly; Jak2V617F mutation and c-kit D816V mutation were detected. Basal tryptase value was 80.4 ng/mL. …
Literature
1.
go back to reference Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Beau MML et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405PubMed Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Beau MML et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405PubMed
2.
go back to reference Xu RZ, Xu Z (2018) Systemic mastocytosis with an associated hematological neoplasm masquerading as overt primary myelofibrosis. Blood 132(24):2613CrossRefPubMed Xu RZ, Xu Z (2018) Systemic mastocytosis with an associated hematological neoplasm masquerading as overt primary myelofibrosis. Blood 132(24):2613CrossRefPubMed
3.
go back to reference Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E et al (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113(13):2895–2901CrossRefPubMed Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E et al (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113(13):2895–2901CrossRefPubMed
Metadata
Title
Systemic Mastocytosis with Associated Primary Myelofibrosis
Authors
Marianna Greco
Giovanni Caocci
Roberto Mascia
Sonia Nemolato
Margherita Deidda
Maria Pina Simula
Maria Pina Barca
Sandra Orrù
Giorgio La Nasa
Publication date
01-04-2020
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 2/2020
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-019-01225-3

Other articles of this Issue 2/2020

Indian Journal of Hematology and Blood Transfusion 2/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine